Physician profile
Mohit Ahuja
NPI 1134339286
$426,916.02
in general payments reported to CMS, 2019-2025
30 companies · $30K in 2025
The $30K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $61K · 2021: $77K · 2022: $58K · 2023: $65K · 2024: $50K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $113K · Travel and Lodging: $15K · Honoraria: $7,700 · Food and Beverage: $6,895 · Consulting Fee: $1,993 · Education: $64.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,395.00 |
| Travel and Lodging | $15,259.35 |
| Honoraria | $7,700.00 |
| Food and Beverage | $6,894.90 |
| Consulting Fee | $1,993.00 |
| Education | $64.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $337,118.39 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33,188.67 | 2021-2025 | Jardiance |
| Amgen INC. | $23,137.10 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Akebia Therapeutics INC | $11,155.52 | 2019-2024 | Auryxia, Vafseo |
| Horizon Therapeutics Plc | $10,636.48 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $5,230.15 | 2019-2025 | Jynarque |
| Lilly USA, LLC | $2,170.31 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $1,672.20 | 2019-2024 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $550.09 | 2021-2025 | Acthar, Terlivaz |
| Fresenius USA Marketing, INC. | $499.23 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $215.78 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $170.41 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $168.63 | 2022-2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $146.08 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $134.17 | 2022-2025 | Tarpeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $125.08 | 2023-2025 | |
| Ardelyx, INC. | $117.76 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $105.80 | 2021-2023 | Benlysta |
| Vanda Pharmaceuticals INC. | $89.63 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $89.43 | 2019-2023 | Ultomiris |
| Scpharmaceuticals INC. | $34.13 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.60 | 2024 | Livtencity |
| Daiichi Sankyo INC. | $20.47 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.35 | 2023 | Oxlumo |
| Travere Therapeutics, INC. | $18.12 | 2024 | |
| Apellis Pharmaceuticals, INC. | $16.49 | 2025 | Empaveli |
| Baxter Healthcare | $16.32 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.59 | 2025 | Tryvio |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.94 | 2025 | |
| Genzyme Corporation | $12.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohit Ahuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.